Home > Boards > US Listed > Biotechs > Adaptimunne Therapeutics (ADAP)

RJ did lower it to 11 after last

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
now invest Member Profile
 
Followed By 44
Posts 11,574
Boards Moderated 1
Alias Born 02/14/07
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2021 7:38:41 AM
Adaptimmune EPS beats by $0.19, beats on revenue Seeking Alpha - 2/25/2021 7:32:42 AM
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update GlobeNewswire Inc. - 2/25/2021 7:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/16/2021 4:16:33 PM
Schedule 13g Edgar (US Regulatory) - 2/16/2021 11:42:52 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 10:04:44 AM
Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021 GlobeNewswire Inc. - 2/11/2021 8:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 1/28/2021 6:37:15 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/16/2020 5:01:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2020 7:37:37 AM
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During ... GlobeNewswire Inc. - 11/20/2020 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 9:10:01 AM
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 9... GlobeNewswire Inc. - 11/19/2020 9:00:00 AM
Adaptimmune to Host Virtual Investor Day on Friday, November 20th GlobeNewswire Inc. - 11/12/2020 8:00:00 AM
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, ... GlobeNewswire Inc. - 11/9/2020 3:18:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 4:20:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 7:41:08 AM
Adaptimmune Reports Q3 Financial Results and Business Update GlobeNewswire Inc. - 11/5/2020 7:30:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 11/4/2020 10:42:34 AM
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020 GlobeNewswire Inc. - 10/22/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 4:48:05 PM
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial GlobeNewswire Inc. - 10/15/2020 4:40:39 PM
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation NetworkNewsWire - 10/2/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/28/2020 10:45:24 AM
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile a... GlobeNewswire Inc. - 8/28/2020 10:30:10 AM
now invest   Sunday, 09/10/17 12:41:52 PM
Re: tpizzazz24 post# 50
Post # of 135 
RJ did lower it to 11 after last earnings report!!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences